Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: Juli who wrote (249)	10/8/1998 2:34:00 AM
From: Steve	Read Replies (1) \| Respond to of 496

My understanding is that Gliadel is in a multi-national phase III study for use in initial surgeries of brain tumors. According to GLFD this will take a couple of years to complete. The only thing that I am aware that they are hoping for soon is Canadian approval of the use of Gliadel in recurrent surgeries. This will lead to a milestone payment from RPR. I believe that Matt Geller is expecting this to occur during this quarter--but then again he said over a year ago that this would be a $39 stock. He is also expecting a new licensing deal to be completed this quarter. I doubt it will happen.